We’re using a technique known as microencapsulation to deliver cell therapies to treat chronic diseases such as type 1 diabetes.
Millions of people around the globe suffer from diabetes
Over 1.5 million Australians have diabetes, 360,000 of which are insulin-dependent as a means of management. Administration of insulin for type 1 diabetes is essential for survival.
Developing new drug delivery systems
We've partnered with the Australian Foundation for Diabetes Research, Norwegian University of Science and Technology and Swedish medical devices company Corline Systems AB to find innovative solutions to treating diabetes.
Together we have created new microcapsule capable of holding cells or agents of therapeutic benefit that can be temporarily inactive and therefore delivered in a controlled fashion. These capsules are capable of selecting the passage of certain molecules within the body.
By allowing the movement of nutrients and hormones, such as insulin, but not of immune cells or large antibodies we're able to protect the cells inside the microcapsules from the recipient's immune system.
This technology is facilitating an environment that fosters cell growth and regeneration.
Controlled drug delivery
These microcapsules offer a simple method to enclose bioactive materials. The technology holds the potential to combat conditions such as insulin dependent diabetes or liver failure by delivering swift therapeutic agents.
Do business with us to help your organisation thrive
We partner with small and large companies, government and industry in Australia and around the world.